Could it be that the trial here is going to look at something different than the big one in the USA? With so few critical ARDS patients here, it is hard to see a useful trial in Australia with same criteria.
Perhaps they might be trialling it on a broader range of patients? Victor Chang Institute specialises in the heart. Perhaps a study looking at changes in key measurements relevant to heart disease in those with COVID-19 (including those with milder symptoms) when treated with Resestemcel-L?
“These stem cells were trialled extensively for patients with cardiac diseases and the beauty of them is it is an off-the-shelf therapy, the stem cells can be administered to any patient and have substantial effects on changing the course of inflammation and the immune response,” Prof Kovacic told the Sunday Telegraph. [https://7news.com.au/lifestyle/health-wellbeing/coronavirus-australia-stem-cell-treatment-for-virus-patients-to-be-trialled-in-sydney-c-1013399]
Mesoblast(?) Australian Covid-19 Trial Victor Chang Cardiac Research Institute, page-15
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |